The mission of the Alzheimer's Association® Business Consortium (AABC) is to advance Alzheimer’s disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of Alzheimer’s research and the goals of its member organizations. They provide leadership and direction to the groups’ areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing. AABC welcomes new member organizations who are aligned in their commitment to research and innovation. To express interest in joining, please email co-chairs Dr. Jacob Donoghue (jake@beacon.bio) or Dr. Ornit Chiba-Falek (ornit.chibafalek@clairigene.com), or Dr. Christopher Weber (cweber@alz.org), facilitator.

Congratulations to the New AABC Co-Chair

Congratulations to Dr. Theresa Devins, who was elected as the new AABC co-chair for a two-year term. Dr. Devins is the Vice President, Clinical Operations, at Cognition Therapeutics. We are delighted to have her serving in this role. The Alzheimer’s Association extends its gratitude to outgoing co-chair Dr. Donoghue for his service to AABC. Under his leadership, AABC has grown in membership and hosted events that have advanced our mission. We look forward to working with the two co-chairs, Dr. Devins and Dr. Chiba-Falek, in the upcoming year and would like to thank everyone for their continued participation.

Welcome New Members

AABC is growing! Welcome to:

» Jeff Eggeling
  Clinical Enrollment, is a Charlottesville, Virginia based boutique biotech agency with a background in recruiting patients for clinical trials including Alzheimer’s and other neurological diseases. Clinical Enrollment utilizes a carefully honed marketing approach using bespoke content, custom video, and algorithm based ad strategies around designated clinical sites to identify qualified and highly engaged patients. Our social-first approach involves supercharging recruitment to ensure benchmarks are met — or exceeded — and working closely with everyone from research study staff to sponsors.

» Laura Brovold
  Rancho BioSciences – Life Science Data Services is an international company offering data curation, data governance and models, bioinformatics analysis, workflows and pipelines, knowledge mining, target profiles, building databases with content, business analyst services to clients in pharmaceutical and biotech companies, foundations, government, and hospitals.

» Mai Nguyen, Marcus Carstensen, Jesse Gomez, and Jeff Waggoner
  OptoCeutics stands at the vanguard of neurotechnology, passionately dedicated to enhancing cognitive health centered around the advanced 40Hz light therapy technology embodied in our flagship product, EVY LIGHT®. This device harnesses the therapeutic potential of light to stimulate brain activity, offering a simple yet powerful tool for individuals experiencing or at risk of cognitive decline.
  The EVY LIGHT operates on the principle of neurostimulation through light, emitting a frequency that resonates at 40Hz, known to be effective in synchronizing brain waves to enhance mental acuity, memory, and focus. The subtle and consistent stimulation provided by EVY LIGHT is designed not only to enhance brain function but also to potentially slow the progression of cognitive decline.
  By integrating this advanced technology into everyday life without the need for invasive procedures, OptoCeutics makes cognitive health care both accessible and practical, aligning with our mission to provide innovative solutions that empower individuals and their providers to take control of their neurological wellness.
Telocyte
Michael Fossel is the editor and senior author for the new Academic Press textbook, Aging: How Aging Works, How We Can Reverse Aging, and Prospects for Curing Aging Diseases. He brought in co-authors from UCSF, Mayo Clinic (5 authors), Lunds University, Swansea University, University of Innsbruck (2 authors), Detroit Medical Center, Wayne State School of Medicine, University of Wisconsin, Harvard Medical School, Pondicherry University, and Houston Methodist.

Cerecin
Lead ketogenic compound tricaprilin with positive ADASCog Ph2 data in RCT mild-moderate AD trial, showed efficacy signals now in migraine and in epilepsy (orphan infantile spasms) presented in 2023 and submitted for publication, pointing to the commonality of metabolic mitochondrial mechanism. A pilot imaging trial on ketosis bioenergetics will test an overall increase in energy metabolism (i.e., greater CMRO2) in AD-typical regions without concurrent changes in CMRGlu. Blood from Ph 2/3 AD trial are being analyzed including metabolomics, and Sunbirdbio’s proprietary sensor platform and optical amplification (APEX) to identify diverse protein biomarkers: from brain/CSF markers to blood markers for diagnosis and tracking of AD, PD, MS and others knowing that a subtyping demands precision and quantification. Phase 3 AD trial grant preparation is in progress. We are always open to collaboration.

PCM Trials
PCM Trials closes second strategic acquisition of 2024:
The Denver Business Journal details PCM Trials’ recent acquisition of EmVenio Research, our second acquisition of 2024. The acquisition grants PCM Trials access to new, mobile community site networks in the United States and United Kingdom. The acquisition of EmVenio Research, along with PCM Trials of Clinical Trial Service in January, make PCM Trials the largest and most experienced local provider of clinical research access on a global scale. Read more here.

EmVenio Research, a PCM Trials company, announces an exclusive partnership with Prime Healthcare and Health Wizz. The EmVenio Research Center at Prime Healthcare combines EmVenio’s expertise in establishing clinical research sites in new and underrepresented communities with Prime’s well-established Hospital and Healthcare network. The approach aims to increase participation in clinical trials by creating community awareness of research and offering those communities local access to global research opportunities, while also expanding the options Prime Healthcare offers its patients. Read more here.

In our most recent webinar, industry thought leaders came together in a panel discussion to consider recent advancements in the DCT ecosystem, specifically focusing on the impact of AI. Interested in reading the key takeaways? Learn how AI is being used to enhance mobile visits in DCTs by fostering global harmonization and setting the stage for more patient-centric care and streamlined processes in our latest blog post.
Upcoming Scientific Meetings

AAIC24
Join us in Philadelphia, USA and online July 28-Aug. 1 as AAIC convenes researchers, clinicians and dementia professionals from all career stages to share breaking research discoveries and clinical practice education that will lead to improvements in diagnosis, risk reduction and treatments for Alzheimer’s disease and other dementia. From basic science to dementia care, every aspect of the field’s growing knowledge of dementia is incorporated into this world-class conference.
Register now at aaic.alz.org.

Join our AABC AAIC Lunch and Reception
The AABC will be hosting a luncheon at AAIC on Monday, July 29 at the Philadelphia Marriott. All AABC members are welcome to join for networking, lunch and a panel of your peers. This will be followed by a reception on Wednesday, July 31st. All AABC members are welcome to join for a networking events at 6pmET. If you have any questions, please contact Ashley Hansen (ahansen@alz.org).

AAIC Advancements: Modernizing Diagnosis
AAIC® Advancements: Modernizing Diagnosis, Sept. 18-19 in Tokyo, Japan and online will feature global perspectives on the science of Alzheimer’s diagnosis, detection and monitoring. Areas of focus include the Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease, Treatment-Related Amyloid Clearance (TRAC), biomarker advancements, clinical case studies and more. Register now at: www.alz.org/modernizing-diagnosis

As science advances and evolves, so do approaches to describing and diagnosing Alzheimer’s disease. In particular, we now have a better understanding of the changes in Alzheimer’s biomarkers throughout the course of the disease. Join the global research community to discuss geographic-specific implications and considerations.

Social Media
Follow our LinkedIn page! We look forward to using the page to foster partnerships and communications.

Join our Slack channel!  We launched a Slack channel in 2022 to encourage open and direct communications between all members. If interested in joining, please reach out to Ashley Hansen (ahansen@alz.org).

Spread the Word
To help us grow AABC, please continue to introduce new members and companies to our group. We also welcome ideas or events for this newsletter so we can better serve you. Please send your suggestions to Ashley Hansen at (ahansen@alz.org).